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Simple Summary: While latest evidence suggests that some patients with recurrent high-grade
serous ovarian cancer may profit from reinduction with platinum-based chemotherapy regimens,
the selection of patients who are likely to respond remains difficult. The present study therefore aimed
to adapt a mathematical model, which used frequently available laboratory values to estimate growth
rates of recurring tumors as an objectifiable surrogate of both therapy response and patient survival.
After clinical validation, the model may help to personalize treatment strategies and thereby increase
survival of affected patients.
Abstract: This study aimed to assess the predictive value of tumor growth rate estimates based on
serial cancer antigen-125 (CA-125) levels on therapy response and survival of patients with recurrent
high-grade serous ovarian cancer (HGSOC). In total, 301 consecutive patients with advanced HG-
SOC (exploratory cohort: n = 155, treated at the Medical University of Vienna; external validation
cohort: n = 146, from the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS)
consortium) were enrolled. Tumor growth estimates were obtained using a validated two-phase
equation model involving serial CA-125 levels, and their predictive value with respect to treatment
response to the next chemotherapy and the prognostic value with respect to disease-specific sur-
vival and overall survival were assessed. Tumor growth estimates were an independent predictor
for response to second-line chemotherapy and an independent prognostic factor for second-line
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chemotherapy use in both univariate and multivariable analyses, outperforming both the predictive
(second line: p = 0.003, HR 5.19 [1.73–15.58] vs. p = 0.453, HR 1.95 [0.34–11.17]) and prognostic values
(second line: p = 0.042, HR 1.53 [1.02–2.31] vs. p = 0.331, HR 1.39 [0.71–2.27]) of a therapy-free
interval (TFI) < 6 months. Tumor growth estimates were a predictive factor for response to third-
and fourth-line chemotherapy and a prognostic factor for third- and fourth-line chemotherapy use in
the univariate analysis. The CA-125-derived tumor growth rate estimate may be a quantifiable and
easily assessable surrogate to TFI in treatment decision making for patients with recurrent HGSOC.
Keywords: ovarian cancer; therapy response; platinum-resistant; recurrence; growth rate
1. Introduction
Despite the recent introduction of new targeted therapies for high-grade serous ep-
ithelial ovarian cancer (HGSOC), platinum-based chemotherapy regimens remain the
cornerstone of primary and recurrent HGSOC. Platinum-based therapies achieve pri-
mary response rates around 80%, and they have an attenuated efficacy during relapse.
Patients enter a cycle of recurrences and remissions, with the response rates and time inter-
vals between recurrences generally decreasing, until the patient dies of their disease [1].
Therefore, research has focused on optimizing the sequences and combinations of avail-
able drugs, which has significantly improved HGSOC outcome in recent years. The use
of platinum-based regimens in patients with recurrent non-platinum-naïve tumors has
been standard practice for the past two decades. Clinical observations of responses after
reinduction have challenged the classical oncologic concept of acquired cellular platinum
resistance due to Darwinian selection [2].
To resolve this issue, a clinical surrogate of therapy response was proposed, which
would predict whether patients would respond to platinum again. The so-called platinum-
free interval (PFI), defined as the time between the last administration of platinum-based
chemotherapy and diagnosis of cancer recurrence, was implemented in three relatively
small studies without special attention to tumor markers in an era when recurrence was
mostly diagnosed radiologically and/or clinically [3–5]. These previous studies have sig-
nificantly shaped the perception of “clinical” platinum resistance and definition of subsets
of patients with HGSOC; these have been adopted in recent years. In a previous study,
patients with a therapy-free interval (TFI) <1 month, <6 months, and between 6 and
12 months were classified as platinum-“refractory,” platinum-“resistant,” and “partially
sensitive” to platinum, respectively. Many clinical trials have adopted this classification.
At the fifth Ovarian Cancer Consensus Conference in Tokyo (2015), PFI was considered
as a TFI of platinum-based chemotherapy (TFIp) that helped to classify patients as “po-
tentially benefiting from platinum-based chemotherapy” or “potentially not benefiting
from platinum-based chemotherapy.” To date, there is no widely recognized predictive
model to facilitate the estimation of platinum response. Although cancer antigen (CA-125)
has been shown to have predictive value, all available studies are short-term models with
absolute cut-offs or doubling times [6]. A re-evaluation of CA-125 with newer quantifiable
statistical methods could help create more personalized strategies in predicting platinum
response and to allow for correct allocation of platinum to only those patients who will
derive actual treatment benefit, even second or third line. Therefore, this was conducted to
assess the predictive and prognostic value of CA-125, based on tumor growth rate estimates
in patients with recurrent HGSOC.
2. Materials and Methods
This study was a retrospective exploratory data analysis of patients with HGSOC,
who underwent primary cytoreductive surgery for advanced-stage disease (International
Federation of Gynecology and Obstetrics (FIGO) IIB–IV). All consecutive patients who
received both primary and recurrence therapy at the Department of Obstetrics and Gyne-
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cology of the Medical University of Vienna between 2000 and 2015 and who were followed
up for at least 60 months comprised the exploratory cohort. The study was conducted in
accordance with the Declaration of Helsinki ethical guidelines and approved by the local
ethics committee (EK1966/2020). Informed consent was obtained from all the patients
prior to sample collection.
Previously published data of the Ovarian Cancer Therapy–Innovative Models Prolong
Survival (OCTIPS) consortium of patients undergoing primary debulking surgery followed
by platinum-based chemotherapy between 2000 and 2013 at the Department of Gynecol-
ogy, Charité Berlin, Germany; Department of Gynecologic Oncology, Leuven, Belgium;
Department of Surgery and Cancer, Imperial College London, London; and the Centre for
Ovarian Cancer Research University of Edinburgh, Western General Hospital, Edinburgh,
UK comprised the validation cohort. In total, 155 patients comprised the exploratory co-
hort, and 146 patients comprised the validation cohort. The exclusion criteria were: Pa-
tients <18 years at the time of primary therapy, patients with concomitant malignancies,
patients who received neoadjuvant therapy, or patients who received oncologic therapy
apart from cytotoxic chemotherapy and/or bevacizumab, such as poly (ADP-ribose) poly-
merase inhibitors.
All cytoreductive surgeries were conducted by trained gynecologic oncology surgeons. Af-
ter surgery, adjuvant platinum-based combination chemotherapy with or without bevacizumab
was administered to all patients. Recurrence therapy consisted of cytotoxic chemotherapy with
or without platinum or bevacizumab, as indicated in the current evidence.
Overall survival (OS) was calculated as the time between primary cytoreductive
surgery and the date of death or last follow-up. The TFI was calculated as the time between
the last therapy dose and recurrence, as documented in the patients’ charts. The therapy
response was classified as a partial response or complete response, as documented in the
patients’ charts.
The tumor growth rate (g) and tumor decay rate (d) were calculated as previously
described by Stein et al. using a biphasic mathematical function (f), by applying serial
CA-125 measurements. The variable “t” describes the time in days after treatment com-
menced, “d describes the tumor decay, and “g” describes the respective tumor growth in
the following equation: f(t) = exp(−d × t) + exp(g × t)− 1 (Figure 1a) [7,8]. For every
patient, growth “g1–g3” and decay “d1–g3” were automatically fitted using nonlinear least
squares for first, second, and third recurrence, respectively. (Figure 1b) If after inspection
the estimated decay–growth curve was deemed inappropriate, “g” and “d” were manually
tweaked to better fit the data. For example, this was done for two patients to estimate “g”
and “d” after the first-line treatment.
The resulting calculated logarithm of growth and decay rate estimates was further
statistically evaluated as suggested by Stein et al. Based on the assumption that growth
rate estimates quantify how fast respective tumors actually increase in size in-vivo, esti-
mates were assessed for both their predictive and prognostic values at the timepoint of
chemotherapy administration.
In the exploratory cohort, sequential CA-125 measurements were done from the
primary surgery to the last follow-up, whereas this was done from the primary surgery to
the first recurrence in the validation cohort. Therefore, the respective assessment of the 3rd
and 4th lines of therapy was waived in the validation cohort.
Statistical analysis was performed using SPSS® (IBM Corp. Released 2016. IBM SPSS
Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.) for Windows and R 3.6.3 (R
Core Team (2020). R: A language and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/ (accessed
on 2 March 2021). Descriptive statistics of all patients in the exploratory and validation
cohorts were computed. Categorical variables were described using percentages (%),
and medians and interquartile ranges were used to describe continuous variables. The cor-
relation between growth rate estimates and overall survival was described by Pearson’s
correlation coefficient.
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subclinical dimensions. As soon as cell growth outnumbers decay, the tumor may re-grow to a 
clinical recurrence. The assumed tumor growth rate (g) constitutes the primary objective variable 
of the present study. (b) Plotted CA125-course of patient no. 164 throughout primary and 
recurrence therapy of a high-grade serous ovarian cancer high-grade serous epithelial ovarian 
cancer (HGSOC) patient undergoing platinum-based chemotherapy. The black lines demonstrate 
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model, which were further evaluated for their predictive and prognostic values. 
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Figure 1. (a) The plotted two-phased mathematical equation f(t) = exp(−d × t) + exp(g × t)− 1
was proposed by Stein et al. to reflect the sum of decay and subsequent growth of a recurrent
solid tumor under therapy. An initial logarithmic decay may shrink the relative tumor size to
subclinical dimensions. As soon as cell growth outnumbers decay, the tumor may re-grow to a
clinical recurrence. The assumed tumor growth rate (g) constitutes the primary objective variable of
the present study. (b) Plotted CA125-course of patient no. 164 throughout primary and recurrence
therapy of a high-grade serous ovarian c ncer high-grade serous e ithelial ovarian canc r (HGSOC)
patient undergoing platinum-based chemotherapy. The black lines demonstrate the respective growth
rate estimates (g1 and g2) calculate applying the two-phased mathematical model, which were
further evaluated for their predictive and prognostic values.
A logistic regression model was fitted to evaluate the growth rate estimate as a p edic-
tor of therapy response. A receiver op rating characte istic (ROC) curve was computed and
the optimal cut-off for the growth rate estimate to predict survival was defined by Youden’s
J-statistics, as previously described [9]. This cut-off, as well as important confounders
such as TFI > 6 months, age at time of therapy > 60 years, platinum-based therapy yes/no,
and FIGO stage (2014) > FIGO IIIc were subsequently used in univariate analyses to deter-
mine their association with response to second-line, third-line, and fourth-line chemother-
apy (using Chi-square tests), and overall survival at the time of secondary cytotoxic
chemotherapy (log-rank tests). Subsequently, multivariable models for both endpoints
(logistic regression models and Cox proportional hazard models) were fitted as deemed
appropriate. For all effect estimates, 95% confidence intervals were computed. For all
statistical tests, p-values < 0.05 were considered statistically significant. p-values serve only
descriptive purposes; hence, no multiplicity corrections were applied.
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3. Results
3.1. Description and Comparison between the Exploratory and Validation Cohorts
Table 1 depicts the characteristics of the patients in the exploratory and validation co-
horts.
Table 1. Descriptive characteristics. Patients treated at the Medical University of Vienna comprised
the exploratory cohort, while patients treated at partner centers of the Ovarian Cancer Therapy–
Innovative Models Prolong Survival (OCTIPS) consortium comprised the validation cohort.
Parameter Exploratory Cohort Validation Cohort
Number of patients 155 146
Age at surgery (years) 58.0 (49.0–66.0) 57.0 (48.8–64.3)
FIGO stage (2014)
II 6 (3.9%) 5 (3.4%)
III 132 (85.2%) 123 (84.3%)
IV 17 (11.0%) 18 (12.3%)
Residual tumor after primary surgery
Yes 48 (30.8%) 50 (34.2%)
No 107 (68.6%) 96 (65.8%)
CA-125 at primary surgery (kU/L) 558.0 (221.5–1491.3) 504 (140.5–1301.0)
Time to nadir (days) 103.5 (73.3–161.3) not available
Log growth rate estimate at 1st recurrence −3.5 (−4.3–−3.1) −3.4 (−4.1–−3.0)
Log decay rate estimate at 1st recurrence −1.3 (−1.5–−1.1) −1.0 (−1.1–−0.9)
Status at last follow-up
Alive 38 (24.5%) 42 (28.8%)
Progression 4 (2.6%) not available
Intercurrent death 26 (16.8%) 18 (12.3%)
Cancer-related death 87 (56.1%) 78 (53.4%)
Duration of follow-up (months) 53.0 (27.0–85.0) 46.0 (28.8–71.5)
TFST (months) 15.0 (8.0–25.5) 14.5 (7.0–23.0)
Available 117 (75.5%) 113 (77.4)
Not available 38 (24.5%) 33 (22.6)
TSST (months) 7.0 (2.5–11.5) 8.0 (3.0–13.0)
Available 73 (47.1%) 68 (46.6%)
Not available 82 (52.9%) 78 (53.4%)
TFI 2nd to 3rd recurrence (months) 5.0 (1.0–10.0) 4.0 (1.0–9.0)
Available 42 (27.1%) 45 (30.8%)
Not available 113 (72.9%) 101 (69.2%)
Values are presented as median (interquartile range) or number (%). CA-125, cancer antigen 125; FIGO, Inter-
national Federation of Gynecology and Obstetrics; TFST, time to first subsequent therapy; TSST, time to second
subsequent therapy; TFI, therapy-free interval.
The key characteristics (patient’s age at the time of upfront debulking, residual tumor,
FIGO stage, and follow-up) of the two cohorts were compared. To describe the effect of
established prognostic factors in both cohorts, univariate and multivariate survival analyses
were performed; FIGO stage (exploratory: p < 0.001, HR 3.12 [1.65–6.22]; validation:
p = 0.01, HR 4.03 [1.76–9.22]); and no residual tumor after primary surgery (exploratory:
p < 0.001, HR 2.90 [1.85–4.55]; validation: p = 0.01, HR 2.51 [1.24–5.07]) were independent
predictors of OS.
A flowchart depicting therapy courses and respective response rates in comparison to
platinum-based chemotherapy and bevacizumab application for both the exploratory and
validation cohorts is given in Figure 2.
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Figure 2. Flowchart depicting therapy courses and respective overall response rates (ORR) in comparison with platinum-
based chemotherapy and bevacizumab application for both exploratory and validation cohort. Dashed boxes describe the
survival status of patients who did not undergo a subsequent therapy line for any reason at a 5-year overall survival follow-
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3.2. Growth Rate Es im e as a Predictor of Therapy Response
The area under the curve (AUC) of the receiver operating characteristic (ROC) curve
was 0.790 (Figure 3). The ideal cut-off for the first recurrence after first-line chemotherapy
treatment was −3.32, calculated with Youden’s J-statistics. The established cut-off was
subsequently used for later recurrences.
Using a cut-off of −3.32, growth rate estimate (p = 0.003, OR 5.19 [1.73–15.58]), ad-
vanced patient age >60 years (p = 0.006, OR 5.32 [1.63–17.38]), and application of platinum-
based chemotherapy (p < 0.001, OR 16.06 [4.48–53.29]) were predictive of the response to
second-line cytotoxic chemotherapy in the multivariable analysis. TFI < 6 months was
only predictive in the univariate analysis (p = 0.005, OR 1.73 [1.29–2.31]), but not in the
multivariable analysis (p = 0.453, HR 1.95 [0.34–11.17]) (Table 2a). The same results were
observed in the validation cohort (Table 2b).
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Figure 3. The area under the curve (AUC) receiver operating characteristic analysis to assess the
predictive value of the logarithm of the growth rate constant in patients with recurrent HGSOC with
the endpoint of complete or partial response to 2nd-line chemotherapy. Youden’s J-statistics was
performed to define −3.32 as an optimal cut-off.
Table 2. (a–b) Predictive factors for response to second-line cytotoxic chemotherapy for HGSOC recurrence in the exploratory




Response to Second-Line Chemotherapy
Univariate Analysis Multivariable Analysis
p-Value OR (95% CI) p-Valu OR (95% CI)
Log growth rate constant >−3.32 <0.001 2.57 (1.60–4.12) 0.003 5.19 (1.73–15.58)
Therapy-free interval >6 mont s 0.005 1.73 (1.29–2.31) 0.453 1.95 (0.34–11.17)
Age at time of therapy >60 years 0.03 1.35 (1.04–1.74) 0.006 5.32 (1.63–17.38)
Platinum-based therapy yes/no <0.001 5.39 (2.92–9.95) <0.001 16.06 (4.48–53.29)
FIGO stage (2014) > FIGO IIIc 0.055 1.69 (0.86–3.34) - -
2b. Parameters
Validation Cohort
Response to Second-Line Chemotherapy
Univariate Analysis Multivariable Analysis
p-Value OR (95% CI) p-Value OR (95% CI)
Log growth rate constant >−3.32 0.008 1.60 (1.10–2.33) 0.03 3.67 (1.13–11.86)
Therapy-free interval >6 months 0.025 1.81 (0.95–3.47) 0.661 1.48 (0.26–8.46)
Age at time of therapy >60 years 0.03 7.58 (1.11–51.66) 0.056 10.15 (0.94–109.25)
Platinum-based therapy yes/no <0.001 2.65 (1.51–4.65) 0.016 5.79 (1.40–24.05)
FIGO stage (2014) > FIGO IIIc 0.048 1.68 (0.89–3.18) - -
CI: Confidence interval, FIGO: International Federation of Gynecology and Obstetrics, OR: Odds ratio.
The growth rate estimate (p = 0.017, HR 1.89 [1.06–3.37]), TFI > 6 months (p = 0.003,
HR 1.71 [1.21–2.41]) and application of platinum-based therapy (p = 0.046, HR 1.94 [1.11–3.40])
remained predictive of a response to third-line chemotherapy only in the univariate anal-
ysis, whereas only application of platinum-based therapy (p = 0.010, HR 1.67 [0.87–3.19])
remained predictive of a response to fourth-line chemotherapy in the univariate analysis.
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There were no significant predictive factors for third- and fourth-line chemotherapy in the
respective multivariable analyses.
The growth rate estimate retains its predictive value in homogenous patient subgroups,
irrespective of the therapy-free interval
To confirm the predictive and prognostic value of the growth rate estimate in a ho-
mogenous cohort, a subgroup analysis was performed for all patients with a TFI > 6 months,
who received platinum-based chemotherapy for the first recurrence and completed all
therapy cycles (n = 69). In this subgroup, the growth rate estimate was associated with
therapy response (p = 0.048, OR 2.46 [0.86–7.98]) and a prognostic factor for OS (p = 0.033,
HR 3.31 [1.74–6.29]) in both univariate analyses. The results were not significant in the
multivariable analyses. The growth rate estimate also retained its predictive ability in the
subgroup of patients with a TFI < 6 months at first recurrence in the exploratory (p = 0.015,
OR 5.00 [0.87–28.86], n = 11) and validation cohorts (p = 0.048, OR 4.0 [0.73–21.84], n = 9)
in the univariate analysis.
3.3. Growth Rate Estimate Is Independently Predictive of Overall Survival
Growth rate estimates for the 1st recurrence were significantly correlated with overall
survival in both the exploratory (r = 0.39, p < 0.001) and validation cohorts (r = 0.44,
p < 0.001). The growth rate estimate (p = 0.005, HR 1.92 [1.22–3.03]) and application of
platinum-based therapy (p < 0.001, HR 2.34 [1.41–3.87]) were predictive of OS at the time of
the first course of second-line chemotherapy in the multivariable analysis. TFI < 6 months
was only prognostic in the univariate, but not in the multivariable analysis (p = 0.014)
(Table 3a). The same results were observed in the validation cohort (Table 3b). Kaplan–
Meier curves depicting the association between OS and growth rate estimates are given in
Figure 4.
Table 3. (a–b) Univariate and multivariate analysis of prognostic factors of overall survival at the time of secondary cytotoxic
chemotherapy for high-grade serous ovarian cancer recurrence in both the exploratory (3a) and validation (3b) cohorts.
Endpoint was patient death irrespective of documented cause.
3a. Parameters
Exploratory Cohort
Prognostic Value for Second-Line Chemotherapy
Univariate Analysis Multivariable Analysis
p-Value HR (95% CI) p-Value
Log growth rate constant > −3.32 0.006 2.13 (1.37–3.32) 0.005 1.92 (1.22–3.03)
Therapy-free interval > 6 months 0.014 1.93 (0.96–3.87) 0.524 1.29 (0.59–2.82)
Age at time of therapy > 60 years 0.005 1.82 (1.17–2.85) - -
Platinum-based therapy yes/no <0.001 2.66 (1.69–4.17) 0.001 2.34 (1.41–3.87)
Bevacizumab received yes/no 0.934 1.02 (0.60–1.76) 0.504 1.25 (0.65–2.38)
No primary surgery residual tumor (R0) 0.045 1.46 (0.93–2.29) - -
FIGO stage (2014) > FIGO IIIc 0.595 1.32 (0.66–2.65) - -
3b. Parameters
Validation Cohort
Prognostic Value for Second-Line Chemotherapy
Univariate Analysis Multivariable Analysis
p-Value HR (95% CI) p-Value
Log growth rate constant >−3.32 <0.001 3.31 (1.74–6.29) 0.002 2.90 (1.50–5.59)
Therapy-free interval >6 months <0.001 1.44 (0.73–2.81) 0.642 1.13 (0.83–1.79)
Age at time of therapy >60 years <0.001 1.58 (1.01–2.48) - -
Platinum-based therapy yes/no 0.001 2.10 (1.30–3.39) 0.015 2.23 (1.17–4.23)
CI: Confidence interval, FIGO: International Federation of Gynecology and Obstetrics, HR: Hazard ratio.
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Figure 4. Kaplan–Meier curves depicting overall survival at the timepoint of secondary cytotoxic
chemotherapy broken down by tumor growth rate estimates at an optimal cut-off of ≤/>−3.32 in
both exploratory and validation cohorts.
For the third-line chemotherapy (n = 73), growth rate estimate (p = 0.040), TFI > 6 months
(p < 0.001), and platinum-based chemotherapy (p = 0.025) were prognostic factors only in
the univariate analysis. For the fourth-line chemotherapy (n = 42), only use of platinum-
based chemotherapy (p = 0.028) remained a prognostic factor in the univariate analysis.
Respective multivariable analyses for responses to third- and fourth-line chemotherapy
showed no significant results.
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4. Discussion
Tumor growth rate estimates based on serial CA-125 levels are independent predictors
of response to second-line chemotherapy and independent prognostic factors of patient
survival after 2nd-line chemotherapy in patients with HGSOC. Tumor growth estimates
outperformed the predictive and prognostic role of TFI < 6 months in the exploratory and
validation cohorts.
The predictive value of tumor growth rates found in this study is in line with previ-
ously published results for renal cell carcinoma and prostate cancer. Stein et al. (2008) used
the model in patients with prostate cancer in a clinical trial and subsequently validated it
using fitting data from five prospective prostate cancer studies. They reported a higher
efficacy of subsequent chemotherapy courses depending on incremental reductions in
tumor growth estimates; they suggested that it was a cost-effective surrogate of patient
survival for future clinical trials [7,8]. A prospective phase II trial of 81 patients with
renal cancer confirmed the predictive value of the model for therapy response using the
Response Evaluation Criteria in Solid Tumors (RECIST) criteria and also described its
potential prognostic value [10]. The predictive and prognostic values of the model were
recently validated in a prospective clinical study of 2353 patients from Project Data Sphere
LLC (Cary, NC, USA). This study emphasized the growing clinical interest in the applica-
tion of mathematical models in improving the understanding of the response to anticancer
treatment [11].
This is the first adept study to evaluate the predictive and prognostic value of the
model by Stein et al. in HGSOC. Tumor growth rate estimates may be promising surrogates
to TFI in treatment decision making. Growth rate estimates may therefore allow the identi-
fication of patients in whom platinum reinduction earlier than 6 months after completion
of the last cycle or beyond the first recurrence may be beneficial.
This observation challenges earlier theories of clonal evolution and acquired common
oncologic cellular resistance, which propose cytotoxic agents after a relapse. Although this
assumption may be applied to other solid carcinomas, this study’s results may be explained
by the confirmed exceptional chemosensitivity of HGSOC to platinum reinductions in
two recent large clinical trials. First, the Mito-8 study, a phase III randomized trial tested
whether intentionally extending the TFIp by avoiding platinum salts during the first relapse
would extend survival. This hypothesis was clearly rejected, underlining the clinical bene-
fits of early platinum reinduction [12]. Second, INOVATYON, a phase III randomized trial,
failed to demonstrate an improvement in OS after a trabectedin/pegylated liposomal dox-
orubicin (PLD) combination instead of carboplatin/PLD for platinum-sensitive HGSOC
recurrence, confirming the efficacy of platinum-based regimens in recurrence [13].
In line with this, preclinical longitudinal studies investigating the molecular adaptions
of HGSOC cells after platinum therapy failed to consistently demonstrate specifically
selected mutations attributable to particular cellular platinum resistance mechanisms,
which may help to identify patients unfit for platinum reinduction. Genomic profiling
before and after treatment showed near-identical genomic landscapes without distinct
mutational adaptions [14–16]. Most mutations appear to exist before primary therapy
and persist throughout the treatment with platinum, suggesting that several clones sur-
vive therapy without accumulating distinct mutations that are attributable to particular
chemoresistances [17].
Recent evidence of the possible benefits of platinum reinduction outlines the urgent
necessity of defining strong predictors of therapy response to allow more personalized
treatment decisions, and subsequently improve survival.
Numerous mathematical models have been proposed to date as potential aids in
clinical decision making such as nomograms to interpret established biomarkers more
comparatively or more complex risk prediction models such as the broadly validated IOTA
ADNEX [18,19]. Of note, mathematical models also face methodological limitations which
have to be considered before application: Apart from rigorous broad clinical multicen-
ter validation, sensitivity and model error analyses should always be performed before
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application at a new center to account for possible systematic confounders not depictable
by the model design. Moreover, mathematical models may only address specific questions
and may be limited in scale as inclusion of more factors may require both methodologically
and computationally intensive numerical integration. In case of the present model fitted
for HGSOC patients, data of two patients had to be manually tweaked as the model failed
to automatically account for prolonged remission times. This issue was already addressed
by the original publication of Stein et al. [20,21].
This study had some limitations. First, as is typical of retrospective studies, its lack
of random patient assignment and selection and possible erroneous data acquisition may
diminish its clinical value. However, its large sample size and long follow-up period
may have ensured the generalizability of our data due to a change in treatment regimens
and existing evidence. Therefore, data from a larger prospective multicenter cohort were
adopted as a validation cohort to minimize the associated bias. Since observations could
be independently confirmed in both cohorts, it may be assumed that our study findings
are generalizable. It is to be noted that growth rate estimates retained both predictive and
prognostic value for 3rd-line chemotherapies only in univariate analyses and failed to prove
significant for 4th-line chemotherapies. Whereas these results may be considered to be
expected due to dwindling patient numbers in respective cohorts, resilient results would be
interesting for this particular subset of patients, which the present study failed to provide.
Moreover, bevacizumab application may be considered a confounding factor for survival
analysis as results of GOG218 and ICON7 trials indicated survival benefits for patients,
including those staged FIGO 4. As the utmost part of patients, however, received primary
treatment before the results of the GOG2018 and ICON7 were published, only a subset of
included patients was treated with bevacizumab in the primary treatment setting [22,23].
Respective treatment differences between exploratory and validation cohort may be ex-
plained by slightly different timepoints of chemotherapy administration (median timepoint
of first chemotherapy administration March 2008 for the exploratory cohort and April
2006 for the validation cohort) as well as by different national treatment standards. Nev-
ertheless, our study findings should be interpreted as exploratory, requiring prospective
validation in larger cohorts before their application in clinical routine.
5. Conclusions
Tumor growth rate estimates based on serial CA-125 levels are independent predictors
of therapy response and prognosis of recurrence in HGSOC, irrespective of TFI. Thereby, tu-
mor growth rate estimates may provide a novel, easily quantifiable, and cost-effective
biomarker of chemotherapy response and tumor recurrence, which may complement
the TFI in therapy decision making and improve personalized treatment strategies. Fur-
ther clinical validation in larger patient cohorts or within the frame of prospective trials
is warranted.
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